Leucemia mieloide crónica: Un modelo terapéutico de biología molecular

Autores:
Suárez Delgado, Sandra Lucía
Polo, Virginia Abello
Solano, María Helena
Tipo de recurso:
Article of journal
Fecha de publicación:
2003
Institución:
Fundación Universitaria de Ciencias de la Salud - FUCS
Repositorio:
Repositorio Digital Institucional ReDi
Idioma:
spa
OAI Identifier:
oai:repositorio.fucsalud.edu.co:001/2245
Acceso en línea:
https://repositorio.fucsalud.edu.co/handle/001/2245
https://doi.org/10.31260/RepertMedCir.v12.n4.2003.337
Palabra clave:
Rights
openAccess
License
Fundación Universitaria de Ciencias de la Salud FUCS - 2018
id FUCS2_8e04971db3f0eeabcae05e76e8bed94c
oai_identifier_str oai:repositorio.fucsalud.edu.co:001/2245
network_acronym_str FUCS2
network_name_str Repositorio Digital Institucional ReDi
repository_id_str
dc.title.spa.fl_str_mv Leucemia mieloide crónica: Un modelo terapéutico de biología molecular
dc.title.translated.eng.fl_str_mv Chronic myeloid leukemia: A therapeutic model of molecular biology
title Leucemia mieloide crónica: Un modelo terapéutico de biología molecular
spellingShingle Leucemia mieloide crónica: Un modelo terapéutico de biología molecular
title_short Leucemia mieloide crónica: Un modelo terapéutico de biología molecular
title_full Leucemia mieloide crónica: Un modelo terapéutico de biología molecular
title_fullStr Leucemia mieloide crónica: Un modelo terapéutico de biología molecular
title_full_unstemmed Leucemia mieloide crónica: Un modelo terapéutico de biología molecular
title_sort Leucemia mieloide crónica: Un modelo terapéutico de biología molecular
dc.creator.fl_str_mv Suárez Delgado, Sandra Lucía
Polo, Virginia Abello
Solano, María Helena
dc.contributor.author.spa.fl_str_mv Suárez Delgado, Sandra Lucía
Polo, Virginia Abello
Solano, María Helena
publishDate 2003
dc.date.accessioned.none.fl_str_mv 2003-12-01 00:00:00
2022-02-21T20:35:33Z
dc.date.issued.none.fl_str_mv 2003-12-01
dc.date.available.none.fl_str_mv 2003-12-01 00:00:00
2022-02-21T20:35:33Z
dc.type.spa.fl_str_mv Artículo de revista
dc.type.eng.fl_str_mv Journal article
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.content.spa.fl_str_mv Text
dc.type.coarversion.spa.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
format http://purl.org/coar/resource_type/c_6501
status_str publishedVersion
dc.identifier.doi.none.fl_str_mv 10.31260/RepertMedCir.v12.n4.2003.337
dc.identifier.issn.none.fl_str_mv 0121-7372
dc.identifier.uri.none.fl_str_mv https://repositorio.fucsalud.edu.co/handle/001/2245
dc.identifier.eissn.none.fl_str_mv 2462-991X
dc.identifier.url.none.fl_str_mv https://doi.org/10.31260/RepertMedCir.v12.n4.2003.337
identifier_str_mv 10.31260/RepertMedCir.v12.n4.2003.337
0121-7372
2462-991X
url https://repositorio.fucsalud.edu.co/handle/001/2245
https://doi.org/10.31260/RepertMedCir.v12.n4.2003.337
dc.language.iso.spa.fl_str_mv spa
language spa
dc.relation.references.spa.fl_str_mv Kantarjian H. Chronic Myelogenous leukemia: disease biology and current and future therapeutic strategies. American Society of Hematology 2000: 90-107.
Druker B. Chronic myelogenous leukemia American Society of Hematology 2001: 87-112.
O'Brien S, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
Okuda K, et al. ARG tyrosine kinase activity is inhibited by ST1571. Blood 2001; 97(8): 2440-2448.
Druker B, et al. Activity or a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344 (14):1038-1042.
Kantarjian H, et al. Hematologic and citognetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346(9):645-52.
Larson R, Wolff S. Chronic myeloid leukemia. En: Wintrobe's Hematology. 10a edición, 2001. Ed. Lippincott Williams y Wilkins. Baltimore, USA, p. 2342-2364.
Mauro M, et al. STI571: Targeting BCR-ABL as therapy for CML. The Oncologist 2001; 6:233-38.
Druker B, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344 (14):1031-37.
Savage D, et al. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002; 346 (9): 683-693.
The Italian Cooperative Study Group on chronic myeloid leukemia. Interferon alfa 2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820-825.
Ohniski K, et al. A randomized trial comparing interferon alpha with busulfan for newly diagnosed chronic myeloid leukemia in chronic phase. Blood 1995; 86: 906-916.
Hehlmann R, et al. Randomized comparison of interferonalpha with busulfan and hydroxiurea in chronic myelogenous leukemia. Blood 1994; 84: 4064-4077.
Guilhot F, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997; 337: 223-229.
Baccarani M. Interferon alfa for chronic myeloid leukemia. Seminars in Hematology 2003; 40 (1):22-33.
Sawyers Ch. Imatinib induces hematologic and citogenetic response in patients with chronic myeloid blast crisis: results of a fase II study. Blood May 2002; 99(10): 3530-3539.
Druker B. Chronic myelogenous leukemia. Hematology 2002:111-135.
dc.relation.bitstream.none.fl_str_mv https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/337/340
dc.relation.citationedition.spa.fl_str_mv Núm. 4 , Año 2003 : Octubre – Diciembre
dc.relation.citationendpage.none.fl_str_mv 194
dc.relation.citationissue.spa.fl_str_mv 4
dc.relation.citationstartpage.none.fl_str_mv 190
dc.relation.citationvolume.spa.fl_str_mv 12
dc.relation.ispartofjournal.spa.fl_str_mv Revista Repertorio de Medicina y Cirugía
dc.rights.spa.fl_str_mv Fundación Universitaria de Ciencias de la Salud FUCS - 2018
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv Fundación Universitaria de Ciencias de la Salud FUCS - 2018
https://creativecommons.org/licenses/by-nc-sa/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Sociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Salud
dc.source.spa.fl_str_mv https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/337
institution Fundación Universitaria de Ciencias de la Salud - FUCS
bitstream.url.fl_str_mv https://repositorio.fucsalud.edu.co/bitstreams/15205686-3af4-4370-ac2f-a1728b1f8d00/download
bitstream.checksum.fl_str_mv c3401ccbdf0ddcc7fbdadf36cfd4474f
bitstream.checksumAlgorithm.fl_str_mv MD5
repository.name.fl_str_mv Repositorio Digital de la Fundación Universitaria de Ciencias de la Salud
repository.mail.fl_str_mv redi@fucsalud.edu.co
_version_ 1828220158142840832
spelling Suárez Delgado, Sandra Lucía8b420ed4fcfdfabfe6136501d1364c94500Polo, Virginia Abello2cbf2025a059ddc1deef97d22cadaee5300Solano, María Helenacfbd69f8e4d28c6e6c3d2a032972d1fc5002003-12-01 00:00:002022-02-21T20:35:33Z2003-12-012003-12-01 00:00:002022-02-21T20:35:33ZSociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la SaludFundación Universitaria de Ciencias de la Salud FUCS - 2018info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/http://purl.org/coar/access_right/c_abf2https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/337Leucemia mieloide crónica: Un modelo terapéutico de biología molecularChronic myeloid leukemia: A therapeutic model of molecular biologyapplication/pdfArtículo de revistaJournal articlehttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionTexthttp://purl.org/coar/version/c_970fb48d4fbd8a8510.31260/RepertMedCir.v12.n4.2003.3370121-7372https://repositorio.fucsalud.edu.co/handle/001/22452462-991Xhttps://doi.org/10.31260/RepertMedCir.v12.n4.2003.337spaKantarjian H. Chronic Myelogenous leukemia: disease biology and current and future therapeutic strategies. American Society of Hematology 2000: 90-107.Druker B. Chronic myelogenous leukemia American Society of Hematology 2001: 87-112.O'Brien S, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.Okuda K, et al. ARG tyrosine kinase activity is inhibited by ST1571. Blood 2001; 97(8): 2440-2448.Druker B, et al. Activity or a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344 (14):1038-1042.Kantarjian H, et al. Hematologic and citognetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346(9):645-52.Larson R, Wolff S. Chronic myeloid leukemia. En: Wintrobe's Hematology. 10a edición, 2001. Ed. Lippincott Williams y Wilkins. Baltimore, USA, p. 2342-2364.Mauro M, et al. STI571: Targeting BCR-ABL as therapy for CML. The Oncologist 2001; 6:233-38.Druker B, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344 (14):1031-37.Savage D, et al. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002; 346 (9): 683-693.The Italian Cooperative Study Group on chronic myeloid leukemia. Interferon alfa 2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820-825.Ohniski K, et al. A randomized trial comparing interferon alpha with busulfan for newly diagnosed chronic myeloid leukemia in chronic phase. Blood 1995; 86: 906-916.Hehlmann R, et al. Randomized comparison of interferonalpha with busulfan and hydroxiurea in chronic myelogenous leukemia. Blood 1994; 84: 4064-4077.Guilhot F, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997; 337: 223-229.Baccarani M. Interferon alfa for chronic myeloid leukemia. Seminars in Hematology 2003; 40 (1):22-33.Sawyers Ch. Imatinib induces hematologic and citogenetic response in patients with chronic myeloid blast crisis: results of a fase II study. Blood May 2002; 99(10): 3530-3539.Druker B. Chronic myelogenous leukemia. Hematology 2002:111-135.https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/337/340Núm. 4 , Año 2003 : Octubre – Diciembre194419012Revista Repertorio de Medicina y CirugíaPublicationOREORE.xmltext/xml2523https://repositorio.fucsalud.edu.co/bitstreams/15205686-3af4-4370-ac2f-a1728b1f8d00/downloadc3401ccbdf0ddcc7fbdadf36cfd4474fMD51001/2245oai:repositorio.fucsalud.edu.co:001/22452024-02-02 13:08:55.999https://creativecommons.org/licenses/by-nc-sa/4.0/Fundación Universitaria de Ciencias de la Salud FUCS - 2018metadata.onlyhttps://repositorio.fucsalud.edu.coRepositorio Digital de la Fundación Universitaria de Ciencias de la Saludredi@fucsalud.edu.co

Publicaciones similares